2160.T
GNI Group Ltd.
グロース · 医薬品 · 医薬品 · JP
JPY 2,805.00
+0.94%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 27.0B | 26.8B | 23.6B | 26.0B | 17.4B |
| Cost of Revenue | 1.5B | 6.8B | 5.6B | 3.6B | 2.7B |
| Gross Profit | 4.0B | 20.0B | 18.0B | 22.4B | 14.7B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 5.5B | 19.0B | 15.8B | 15.3B | 11.0B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 359.0M | 1.7B | 485.6M | 619.0M | 520.2M |
| Total Operating Expenses | 5.8B | 20.7B | 16.3B | 15.9B | 11.5B |
| Cost and Expenses | 32.5B | 30.3B | 22.2B | 12.9B | 16.0B |
| Operating Income (EBIT) | (5.4B) | (3.5B) | 1.4B | 13.1B | 1.4B |
| Non-Operating | |||||
| Interest Income | 135.0M | 578.0M | 707.8M | 771.5M | 259.8M |
| Interest Expense | 588.0M | 1.8B | 1.9B | 1.3B | 869.9M |
| Net Interest Income | (453.0M) | (1.2B) | (1.2B) | (479.2M) | (610.1M) |
| Other Non-Op Income/Expense | 97.0M | 527.0M | 2.4B | 9.1B | 664.7M |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (3.2B) | (4.6B) | 238.2M | 12.6B | 767.9M |
| Income Tax Expense | 189.0M | 2.5B | 247.7M | 3.1B | 1.6B |
| Bottom Line | |||||
| Net Income | (5.8B) | (4.2B) | 1.1B | 8.1B | 388.0M |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (9.3B) | (7.2B) | (9.6M) | 9.5B | (868.3M) |
| Per Share | |||||
| Basic EPS | (¥109) | (¥81) | ¥22 | ¥170 | ¥8 |
| Diluted EPS | (¥109) | (¥81) | ¥21 | ¥166 | ¥8 |
| Revenue Per Share | ¥486 | ¥512 | ¥472 | ¥545 | ¥367 |
| Shares | |||||
| Basic Shares Outstanding | 55.7M | 52.5M | 50.0M | 47.8M | 47.5M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | (2.3B) | 2.4B | 13.7B | — |
| D&A | — | 1.1B | 983.2M | 608.4M | — |
| EBIT | (5.4B) | (3.5B) | 1.4B | 13.1B | 1.4B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026